Personalis (PSNL) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Personalis

NasdaqGM•Healthcare•Diagnostics & Research

$17.20+0.37(0.02%)Market closed

Market Cap

$1.70B

P/S

24.4x

P/B

7.2x

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.

How this company scores

WeakMetricSide Score: 36/100

Strongest: Balance Sheet & Red Flags (21/25); weakest: Growth (2/25).

Profitability7/25

Growth2/25

Balance Sheet & Red Flags21/25

Cash & Earnings Quality6/25

Strengths

Low leverageImproving leverageNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 24.4x5y range 0.8x – 24.4x

Currently above its 20-quarter median.

P/B · 7.2x5y range 0.4x – 7.2x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.70B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $69.67M
Q. Revenue: $22.36M
TTM EBITDA: $-104.56M
TTM Op. Income: $-114.31M
Q. Op. Income: $-33.59M
TTM Net Income: $-107.18M
Q. Net Income: $-31.68M
EPS: $-0.3
Shares Out.: $105.42M

$69.67M in TTM revenue declined 13.3% YoY, reaching $22.36M last quarter. TTM EBITDA of $-104.56M and TTM operating income of $-114.31M show growth is flowing through to the bottom line. However, net income is negative at $107.18M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 13% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 21.2%
EBITDA Margin: -139.5%
Op. Margin: -150.2%
Net Margin: -141.7%

Op. margin of -150.2% is down 23.5% YoY — costs are rising relative to revenue. Net margin at -141.7% and gross margin of 21.2% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 19% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 24.4x
P/B Ratio: 7.2x

P/S of 24.4x and P/B of 7.2x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $312.13M
Cash: $93.97M
Long-Term Debt: $898,000
Book Value: $235.16M
D/E Ratio: 0.0
Debt/EBITDA: N/A

With $312.13M in assets and $898,000 in long-term debt, D/E is 0.0and book value is $235.16M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-25.77M
TTM Free Cash Flow: $-100.97M
FCF Margin: -144.9%
FCF / Net Income: 0.9

TTM FCF of $-100.97M on $-25.77M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 5 consecutive quarters — a weakening trend.